Mutations of the BRAF gene in human cancer (original) (raw)

References

  1. Peyssonnaux, C. & Eychène, A. The Raf/MEK/ERK pathway: new concepts of activation. Biol. Cell 93, 53–62 (2001)
    Article CAS PubMed Google Scholar
  2. Avruch, J. A. et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog. Horm. Res. 56, 127–155 (2001)
    Article CAS PubMed Google Scholar
  3. Kolch, W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 351, 289–305 (2000)
    Article CAS PubMed PubMed Central Google Scholar
  4. Vogelstein, B. et al. Genetic alterations during colorectal-tumour development. N. Engl. J. Med. 319, 525–532 (1988)
    Article CAS PubMed Google Scholar
  5. van't Veer, L. J. et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell Biol. 9, 3114–3116 (1989)
    Article CAS Google Scholar
  6. Caduff, R. F., Svoboda-Newman, S. M., Ferguson, A. W., Johnston, C. M. & Frank, T. S. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumours. Am. J. Surg. Pathol. 23, 323–328 (1999)
    Article CAS PubMed Google Scholar
  7. Daya-Grosjean, L., Dumaz, N. & Sarasin, A. The specificity of p53 mutation spectra in sunlight induced human cancers. J. Photochem. Photobiol. B 28, 115–124 (1995)
    Article CAS PubMed Google Scholar
  8. Halaban, R. The regulation of normal melancyte proliferation. Pigment Cell Res. 13, 4–14 (2000)
    Article CAS PubMed Google Scholar
  9. Busca, R. et al. Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes. EMBO J. 19, 2900–2910 (2000)
    Article CAS PubMed PubMed Central Google Scholar
  10. Johnson, L. N., Lowe, E. D., Noble, M. E. & Owen, D. J. The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett. 430, 1–11 (1998)
    Article CAS PubMed Google Scholar
  11. Hemmer, W., McGlone, M., Tsigelny, I. & Taylor, S. S. Role of the glycine triad in the ATP-binding site of cAMP-dependent protein kinase. J. Biol. Chem. 272, 16946–16954 (1997)
    Article CAS PubMed Google Scholar
  12. Grant, B. D., Hemmer, W., Tsigelny, I., Adams, J. A. & Taylor, S. S. Kinetic analyses of mutations in the glycine-rich loop of cAMP-dependent protein kinase. Biochemistry 37, 7708–7715 (1998)
    Article CAS PubMed Google Scholar
  13. Odawara, M. et al. Human diabetes associated with a mutation in the tyrosine kinase domain of the insulin receptor. Science 245, 66–68 (1989)
    Article ADS CAS PubMed Google Scholar
  14. Cooke, M. P. & Perlmutter, R. M. Expression of a novel form of the fyn proto-oncogene in hematopoietic cells. New Biol. 1, 66–74 (1989)
    CAS PubMed Google Scholar
  15. Mason, C. S. et al. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J. 18, 2137–2148 (1999)
    Article CAS PubMed PubMed Central Google Scholar
  16. Marais, R., Light, Y., Paterson, H. F., Mason, C. S. & Marshall, C. J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J. Biol. Chem. 272, 4378–4383 (1997)
    Article CAS PubMed Google Scholar
  17. Zhang, B. H. & Guan, K. L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 19, 5429–5439 (2000)
    Article CAS PubMed PubMed Central Google Scholar
  18. Vojtek, A. B. & Der, C. J. Increasing complexity of the Ras signalling pathway. J. Biol. Chem. 273, 19925–19928 (1998)
    Article CAS PubMed Google Scholar
  19. Mulcahy, L. S., Smith, M. R. & Stacey, D. W. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature 313, 241–243 (1985)
    Article ADS CAS PubMed Google Scholar
  20. Stacey, D. W., DeGudicibus, S. R. & Smith, M. R. Cellular ras activity and tumour cell proliferation. Exp. Cell Res. 171, 232–242 (1987)
    Article CAS PubMed Google Scholar
  21. Favata, M. F. et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623–18632 (1998)
    Article CAS PubMed Google Scholar
  22. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N. Engl. J. Med. 344, 1031–1037 (2001)
    CAS PubMed Google Scholar
  23. Rozycka, M., Collin, N., Stratton, M. R. & Wooster, R. Rapid detection of DNA sequence variants by conformation sensitive capillary electrophoresis. Genomics 70, 34–40 (2000)
    Article CAS PubMed Google Scholar
  24. Mittnacht, S., Paterson, H., Olson, M. F. & Marshall, C. J. Ras signalling is required for inactivation of the tumour suppressor pRb cell-cycle control protein. Curr. Biol. 7, 219–221 (1997)
    Article CAS PubMed Google Scholar

Download references

Acknowledgements

We would like to thank all the patients who donated samples for these studies, the UK Children's Cancer Study Group for provision of paediatric primary tumour samples, the NCCGP for provision of cord blood control DNA samples, and W. Haynes for assistance with preparation of the manuscript. We would also like to acknowledge the Wellcome Trust, Institute of Cancer Research and Cancer Research UK for support. C.J.M. is a Gibb life fellow of the Cancer Research UK. G.P. and A.C. are funded in part by Regione Autonoma della Sardegna. B.A.G. is supported by Breakthrough Breast Cancer.

Author information

Author notes

  1. Helen Davies, Graham R. Bignell, Charles Cox and Philip Stephens: These authors contributed equally to this work

Authors and Affiliations

  1. Cancer Genome Project, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, CB10 1SA
    Helen Davies, Graham R. Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, William Bottomley, Neil Davis, Ed Dicks, Rebecca Ewing, Yvonne Floyd, Kristian Gray, Sarah Hall, Rachel Hawes, Jaime Hughes, Vivian Kosmidou, Andrew Menzies, Catherine Mould, Adrian Parker, Claire Stevens, Stephen Watt, Richard Wooster, Michael R. Stratton & P. Andrew Futreal
  2. Cancer Research UK Centre for Cell and Molecular Biology, Chester Beatty Labs, Institute of Cancer Research, London, SW3 6JB, UK
    Mathew J. Garnett, Steven Hooper, Rebecca Wilson, Hugh Paterson, Richard Marais & Christopher J. Marshall
  3. Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
    Hiran Jayatilake & Michael R. Stratton
  4. Section of Molecular Carcinogenesis, Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
    Colin Cooper, Janet Shipley & Richard Wooster
  5. Section of Paediatrics, Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
    Darren Hargrave & Katherine Pritchard-Jones
  6. Department of Pathology, Western Infirmary, University of Glasgow, S11 6NT, UK
    Barry A. Gusterson
  7. Department of Biology, YCR Cancer Research Unit, University of York, York, YO10 5YW, UK
    Norman Maitland
  8. Queensland Institute of Medical Research, RBH Post Office Herston, Queensland, 4029, Australia
    Georgia Chenevix-Trench
  9. Department of Pathology, Duke University Medical Centre, Durham, North Carolina, 27710, USA
    Gregory J. Riggins & Darell D. Bigner
  10. Department of Surgery, Duke University Medical Centre, Durham, North Carolina, 27710, USA
    Adrienne Flanagan, Hilliard F. Seigler & Timothy L. Darrow
  11. Institute of Molecular Genetics, C.N.R, Loc. Tramariglio, Alghero, 07040, Italy
    Giuseppe Palmieri
  12. Department of Pathology, University of Sassari, Azienda USL1, Sassari, 07100, Italy
    Antonio Cossu
  13. Royal Free & University College Medical School, London, WC1E 6JJ, UK
    Adrienne Flanagan
  14. Royal Brompton Hospital, London, SW3 6NP, UK
    Andrew Nicholson
  15. Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong
    Judy W. C. Ho
  16. Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong
    Suet Y. Leung & Siu T. Yuen
  17. Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, 19104, USA
    Barbara L. Weber

Authors

  1. Helen Davies
  2. Graham R. Bignell
  3. Charles Cox
  4. Philip Stephens
  5. Sarah Edkins
  6. Sheila Clegg
  7. Jon Teague
  8. Hayley Woffendin
  9. Mathew J. Garnett
  10. William Bottomley
  11. Neil Davis
  12. Ed Dicks
  13. Rebecca Ewing
  14. Yvonne Floyd
  15. Kristian Gray
  16. Sarah Hall
  17. Rachel Hawes
  18. Jaime Hughes
  19. Vivian Kosmidou
  20. Andrew Menzies
  21. Catherine Mould
  22. Adrian Parker
  23. Claire Stevens
  24. Stephen Watt
  25. Steven Hooper
  26. Rebecca Wilson
  27. Hiran Jayatilake
  28. Barry A. Gusterson
  29. Colin Cooper
  30. Janet Shipley
  31. Darren Hargrave
  32. Katherine Pritchard-Jones
  33. Norman Maitland
  34. Georgia Chenevix-Trench
  35. Gregory J. Riggins
  36. Darell D. Bigner
  37. Giuseppe Palmieri
  38. Antonio Cossu
  39. Adrienne Flanagan
  40. Andrew Nicholson
  41. Judy W. C. Ho
  42. Suet Y. Leung
  43. Siu T. Yuen
  44. Barbara L. Weber
  45. Hilliard F. Seigler
  46. Timothy L. Darrow
  47. Hugh Paterson
  48. Richard Marais
  49. Christopher J. Marshall
  50. Richard Wooster
  51. Michael R. Stratton
  52. P. Andrew Futreal

Corresponding author

Correspondence toRichard Wooster.

Ethics declarations

Competing interests

The authors declare that they have no competing financial interests.

Supplementary information

41586_2002_BFnature00766_MOESM1_ESM.xls

Supplementary Table 1: Primer sequences used to amplify BRAF, HRAS, KRAS and NRAS; BRAF mutations; BRAF polymorphisms; RAS mutations; Full list of cell lines screened (XLS 69 kb)

Rights and permissions

About this article

Cite this article

Davies, H., Bignell, G., Cox, C. et al. Mutations of the BRAF gene in human cancer.Nature 417, 949–954 (2002). https://doi.org/10.1038/nature00766

Download citation